Bone targeted microenvironment actuated engineered exosomes for precision therapy of IBD associated bone loss.

Bioact Mater · 2026 · PMC13226840 · PMID 42238026

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

showed a trendp = 0.053so close (0.05 < p ≤ 0.1)

Importantly, Il1 8 mRNA in bone did not increase and instead showed a trend toward lower expression (p = 0.053), while Il18r1 expression was unchanged (p = 0.81) (Supporting Fig. 2 G).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.